Help for eligible patients concerned about paying for XOLAIR
|
|
Learn more:
|
|
Please see product and important safety information
Program Overview
The XOLAIR Co-Pay Card Program assists eligible patients with their co-pay costs for XOLAIR.
If your patient qualifies, they can apply for the XOLAIR Co-pay Card through:
- A participating specialty pharmacy
- The Macaluso Group (TMG)*
Eligible patients may have access to up to $4000 over a period of 12 consecutive months to assist with their co-payment of Xolair
Patients are responsible for 20% of their co-payment (eg, for a co-payment of $100, a patient would pay $20).
Participating patients in the program will receive notification approximately 2 months prior to when their co-pay card nears its exhaustion limit. Patients may re-enroll when their 12 consecutive enrollment months have elapsed.
Qualified Participants
The XOLAIR Co-pay Card Program is available through:
- Participating Specialty Pharmacies (SPs)
- Alternate Injection Centers (AICs)
- Hospital Outpatient Departments (HOPDs)
- Buy and bill physicians
- Healthcare Providers (HCPs)
Eligible patients:
- Are taking XOLAIR for its approved use
- Must obtain XOLAIR through one of the participating Specialty Pharmacies or treatment through a buy and bill office, alternate injection center (AIC) or hospital outpatient department (HOPD)
- Are at least 18 years of age; or if between the ages of
12-17, the card must be managed by a guardian who is over 18
- May not be a participant in charitable fund sources (ie, the Genentech® Access to Care Foundation [GATCF])
- May not be a participant in any federally or state-funded healthcare programs (eg, Medicare, Medicaid, TRICARE)
If you or your patients/caregivers have any questions or concerns about the program, please call The Macaluso Group (TMG) at 1-877-411-8641.
XOLAIR Co-pay Card Program Terms and Conditions:
- Patients must meet the Eligibility Requirements
- The XOLAIR Co-pay Card provides drug co-pay assistance for up to $4000 over 12 consecutive months for eligible patients. Patients are responsible for 20% of their drug co-pay
- This promotion cannot be combined with any other programs, offers or discounts
- A prescription for XOLAIR must be filled in order to use this co-pay card
- Patients may wish to consult with their insurance carrier concerning any limitations that may apply to this program under their insurance policy
- Limit one co-pay card per purchase
 |
| |
| |
How patients enroll in the XOLAIR
Co-pay Card Program: |
|
|
| |
|
|
|
| |
- Upon approval for XOLAIR, the patient is contacted by the participating specialty pharmacy or his or her healthcare professional.
- Patient expresses concern about his or her co-pay for XOLAIR and is made aware of the XOLAIR Co-pay Card Program.
- Healthcare professional advises the patient to call his/her participating specialty pharmacy or The Macaluso Group at (877) 411-8641 to ensure he/she meets eligibility criteria.
- A XOLAIR Co-pay Card number is assigned for eligible patients. This number is given to the patient over the phone and may be used immediately. The physical card is then mailed to the patient with a welcome letter
- Patient informs the specialty pharmacy or healthcare professional of their XOLAIR Co-pay Card enrollment and number
- The participating specialty pharmacy or healthcare professional charges 80% of the patient's co-pay, up to $4000 over 12 consecutive months, to the XOLAIR Co-pay Card. The patient is responsible for the remaining 20% of the XOLAIR drug co-pay
- Healthcare professional reminds patients to:
- Present the XOLAIR Co-pay Card at the time of payment for each treatment
- Verify the XOLAIR Co-pay Card is being applied
each month on their bills
|
|
|
| |
|
|
|
|
 |
|
| |
| |
How healthcare professionals, HOPDs or
AICs enroll their offices into the XOLAIR
Co-pay Card Program |
|
|
| |
|
|
|
| |
1a. Healthcare Professional Office
Work with your XOLAIR Clinical Specialist to identify
the primary contact for transactions with the
XOLAIR Co-pay Card.
1b. Hospital Outpatient Department or Alternate
Injection Center
Work with your XOLAIR Clinical Specialist to identify
where the XOLAIR Co-pay Card should be processed
(eg, patient financial services, billing).
2. The healthcare professional, hospital outpatient
department or alternate injection center should call
The Macaluso Group at (877) 411-8641.
3. The Macaluso Group provides a 16-digit number to be
processed through the credit card billing machine, as
well as a user name and password for enrolling
the patient on The Macaluso Group's website.
4. XOLAIR Co-pay Cards may be run within 48 hours
of enrollment.
|
|
|
| |
|
|
|
|
|
For a list of participating specialty pharmacies, click here.
For more information on the XOLAIR Co-Pay Card Program, click here.
*The XOLAIR Co-pay Card Program is serviced by The Macaluso Group.
INDICATION
XOLAIR® (omalizumab) for subcutaneous use is indicated for adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids.
XOLAIR has been shown to decrease the incidence of asthma exacerbations in these patients.
|
Important Limitations of Use
|
|
|
|
 |
XOLAIR is not indicated for treatment of other allergic conditions |
|
|
|
XOLAIR is not indicated for the relief of acute bronchospasm or
status asthmaticus |
|
|
|
XOLAIR is not indicated for use in pediatric patients less than
12 years of age |
IMPORTANT SAFETY INFORMATION
|
WARNING: Anaphylaxis
Anaphylaxis presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of XOLAIR. Anaphylaxis has occurred as early as after the first dose of XOLAIR, but also has occurred beyond 1 year after beginning regularly administered treatment. Because of the risk of anaphylaxis, observe patients closely for an appropriate period of time after XOLAIR administration. Health care providers administering XOLAIR should be prepared to manage anaphylaxis that can be life-threatening. Inform patients of the signs and symptoms of anaphylaxis and instruct them to seek immediate medical care should symptoms occur (see Warnings and Precautions: Anaphylaxis).
|
|
|
|
XOLAIR should only be administered in a healthcare setting by healthcare providers prepared to manage anaphylaxis that can be life-threatening. |
|
|
|
XOLAIR should not be administered to patients who have experienced a severe hypersensitivity reaction to XOLAIR or any ingredient of XOLAIR (see Warnings and Precautions). XOLAIR should be discontinued in patients who experience a severe hypersensitivity reaction. |
|
|
|
Malignant neoplasms were observed in 20 of 4127 (0.5%) XOLAIR-treated patients compared with 5 of 2236 (0.2%) control patients in clinical studies of asthma and other allergic disorders. |
|
|
|
XOLAIR has not been shown to alleviate asthma exacerbations acutely. Do not use XOLAIR to treat acute bronchospasm or status asthmaticus. |
|
|
|
A constellation of signs and symptoms including arthritis/arthralgia, rash (urticaria or other forms), fever and lymphadenopathy similar to serum sickness have been reported in post-approval use of XOLAIR in some patients. Physicians should stop XOLAIR if a patient develops this constellation of signs and symptoms. |
|
|
|
Patients should be given and instructed to read the accompanying Medication Guide before starting treatment and before each subsequent treatment. |
|
|
|
Do not abruptly discontinue corticosteroid use upon initiation of XOLAIR therapy. Decrease corticosteroids gradually under the direct supervision of a physician. |
|
|
|
In patients ≥12 years of age, the most commonly observed adverse reactions (>1% more frequent in XOLAIR-treated patients) from 4 placebo-controlled asthma studies were arthralgia (8%), pain (general) (7%), leg pain (4%), fatigue (3%), dizziness (3%), fracture (2%), arm pain (2%), pruritus (2%), dermatitis (2%), and earache (2%). |
|
|
|
The adverse events most frequently resulting in clinical intervention (e.g. discontinuation of XOLAIR, or the need for concomitant medication to treat an adverse event), in either placebo-controlled or other controlled asthma studies, were injection site reaction (45%), viral infections (23%), upper respiratory tract infection (20%), sinusitis (16%), headache (15%), and pharyngitis (11%). These events were observed at similar rates in XOLAIR-treated patients and control patients. |
|
|
